Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496

Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib

Tartarone, A., Lazzari, C., Lerose, R., Conteduca, V., Improta, G., Zupa, A., Bulotta, A., Aieta, M., & Gregorc, V. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.05.020 · Cited by 63

The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma

Huang, Y.-H., Hsu, K.-H., Tseng, J., Chen, K., Hsu, C.-H., Su, K., Chen, J. J. W., Chen, H., Yu, S., Yang, T., et al. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2017.512 · Cited by 62

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas

Jorge, S. E., Lucena-Araujo, A. R., Yasuda, H., Piotrowska, Z., Oxnard, G. R., Rangachari, D., Huberman, M. S., Sequist, L. V. D., Kobayashi, S. S., & Costa, D. B. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1541 · Cited by 60

Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer

Liu, Y., Tsai, M., Wu, S., Chang, T., Tsai, T.-H., Gow, C., Chang, Y., & Shih, J. (2019) · International Journal of Cancer · doi:10.1002/ijc.32487 · Cited by 60

Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung Cancer

Spaans, J. N., & Goss, G. D. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00190 · Cited by 57

Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations

Yeo, C. D., Park, K. H., Park, C. K., Lee, S. H., Kim, S. J., Yoon, H. K., Lee, Y. S., Lee, E. J., Lee, K. Y., & Kim, T. J. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.004 · Cited by 59

Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations

Starrett, J. H., Guernet, A. A., Cuomo, M. E., Poels, K. E., van Rosenburgh, I. K. V. A., Nagelberg, A. L., Farnsworth, D., Price, K. S., Khan, H., Ashtekar, K. D., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3819 · Cited by 62

Genes and Pathology of Non-Small Cell Lung Carcinoma

Sakashita, S., Sakashita, M., & Tsao, M. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.12.008 · Cited by 56

The Role of microRNAs in the Regulation of Apoptosis in Lung Cancer and Its Application in Cancer Treatment

Othman, N., & Nagoor, N. H. (2014) · BioMed Research International · doi:10.1155/2014/318030 · Cited by 57

BTLA Expression in Stage I–III Non–Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical Outcomes

Li, X., Xu, Z., Cui, G., Li, Y., & Zhang, X. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s232234 · Cited by 56

Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence

Wang, X., Goldstein, D., Crowe, P. J., & Yang, J. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s94745 · Cited by 55

Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer

Albitar, M. X., Sudarsanam, S., Ma, W., Jiang, S., Chen, W., Funari, V. A., Blocker, F., & Agersborg, S. S. (2018) · Oncotarget · doi:10.18632/oncotarget.24455 · Cited by 54

Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure

Sasaki, S., Yoshioka, Y., Ko, R., Katsura, Y., Namba, Y., Shukuya, T., Kido, K., Iwakami, S., Tominaga, S., & Takahashi, K. (2015) · Respiratory Investigation · doi:10.1016/j.resinv.2015.07.001 · Cited by 53

Combined Inhibitions of Glycolysis and AKT/autophagy Can Overcome Resistance to EGFR-targeted Therapy of Lung Cancer

Ye, M., Wang, S., Wan, T., Jiang, R., Qiu, Y., Pei, L., Pang, N., Huang, Y., Huang, Y., Zhang, Z., et al. (2017) · Journal of Cancer · doi:10.7150/jca.21035 · Cited by 52

A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives

do Amaral, D. N., Lategahn, J., Fokoue, H. H., da Silva, E. M. B., Sant’Anna, C. M. R., Rauh, D., Barreiro, E. J., Laufer, S., & Lima, L. M. (2019) · Scientific Reports · doi:10.1038/s41598-018-36846-7 · Cited by 52

KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR

Nakatani, K., Yamaoka, T., Ohba, M., Fujita, K., Arata, S., Kusumoto, S., Taki-Takemoto, I., Kamei, D., Iwai, S., Tsurutani, J., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0591 · Cited by 55

Progression of EGFR-Mutant Lung Adenocarcinoma is Driven By Alveolar Macrophages

Wang, D.-H., Lee, H., Yoon, D. K., Berry, G. J., Wheeler, T. M., Sugarbaker, D. J., Kheradmand, F., Engleman, E. G., & Burt, B. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2597 · Cited by 50

Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung Cancer

Hassanein, M., Hight, M. R., Buck, J. R., Tantawy, M. N., Nickels, M. L., Hoeksema, M. D., Harris, B. K., Boyd, K. L., Massion, P. P., & Manning, H. C. (2015) · Molecular Imaging and Biology · doi:10.1007/s11307-015-0862-4 · Cited by 50

Large cell carcinoma of the lung: A tumor in search of an author. A clinically oriented critical reappraisal

Pelosi, G., Barbareschi, M., Cavazza, A., Graziano, P., Rossi, G., & Papotti, M. G. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.008 · Cited by 50

Forkhead box K2 promotes human colorectal cancer metastasis by upregulating ZEB1 and EGFR

Du, F., Qiao, C., Li, X., Chen, Z., Liu, H., Wu, S., Hu, S., Qiu, Z., Qian, M., Tian, D., et al. (2019) · Theranostics · doi:10.7150/thno.31716 · Cited by 50

DUSP1 Expression Induced by HDAC1 Inhibition Mediates Gefitinib Sensitivity in Non–Small Cell Lung Cancers

Lin, Y.-C., Lin, Y.-C., Shih, J., Huang, W., Chao, S.-W., Chang, Y., & Chen, C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1150 · Cited by 50

Next Generation Sequencing in Non-Small Cell Lung Cancer: New Avenues Toward the Personalized Medicine

Coco, S., Truini, A., Vanni, I., Bello, M. G. D., Alama, A., Rijavec, E., Genova, C., Barletta, G., Sini, C., Burrafato, G., et al. (2014) · Current Drug Targets · doi:10.2174/1389450116666141210094640 · Cited by 51

Epithelial‐to‐mesenchymal transition and its role in EGFR‐mutant lung adenocarcinoma and idiopathic pulmonary fibrosis

Sakuma, Y. (2017) · Pathology International · doi:10.1111/pin.12553 · Cited by 48

Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer

Xu, J., Wang, J., & Zhang, S. (2017) · Oncotarget · doi:10.18632/oncotarget.21164 · Cited by 52

Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle

Patel, H., Pawara, R. H., Ansari, A., Noolvi, M. N., & Surana, S. J. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.03.039 · Cited by 47

Tumor-educated platelet as liquid biopsy in lung cancer patients

Liu, L., Lin, F., Ma, X., Chen, Z., & Yu, J. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102863 · Cited by 46

Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M.

Costa, D. B., & Kobayashi, S. S. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.05.05 · Cited by 46

Long non-coding RNAs associated with non-small cell lung cancer

Zhan, Y., Zang, H., Feng, J., Lu, J., Chen, L., & Fan, S. (2017) · Oncotarget · doi:10.18632/oncotarget.20088 · Cited by 46

Plasma microRNA alterations between EGFR-activating mutational NSCLC patients with and without primary resistance to TKI

Ma, Y., Pan, X., Xu, P., Mi, Y., Wang, W., Wu, X., He, Q., Liu, X., Tang, W., & An, H. (2017) · Oncotarget · doi:10.18632/oncotarget.19874 · Cited by 46

MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib

Ninomiya, K., Ohashi, K., Makimoto, G., Tomida, S., Higo, H., Kayatani, H., Ninomiya, T., Kubo, T., Ichihara, E., Hotta, K., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20326-z · Cited by 45

Metabolic advantages and vulnerabilities in brain metastases

Ciminera, A. K., Jandial, R., & Termini, J. S. (2017) · Clinical & Experimental Metastasis · doi:10.1007/s10585-017-9864-8 · Cited by 46

Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non–small cell lung cancer

Hidaka, N., Iwama, E., Kubo, N., Harada, T., Miyawaki, K., Tanaka, K., Okamoto, I., Baba, E., Akashi, K., Sasaki, H., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.02.019 · Cited by 44

Long non-coding RNA LOC554202 promotes acquired gefitinib resistance in non-small cell lung cancer through upregulating miR-31 expression

He, J., Jin, S., Zhang, W. Y., Wu, D., Li, J., Xu, J., & Gao, W. (2019) · Journal of Cancer · doi:10.7150/jca.35097 · Cited by 43

New Treatment Options for Lung Adenocarcinoma - in View of Molecular Background

Bittner, N., Ostoros, G., & Géczi, L. (2013) · Pathology & Oncology Research · doi:10.1007/s12253-013-9719-9 · Cited by 42

Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer

Husain, H., Scur, M. D., Murtuza, A., Bui, N. Q., Woodward, B. D., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0105 · Cited by 44

Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non‐small cell lung cancer

Sacher, A. G., Janne, P. A., & Oxnard, G. R. (2014) · Cancer · doi:10.1002/cncr.28723 · Cited by 42

Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer

Zhao, J. Y., Guerrero, A., Kelnar, K., Peltier, H. J., & Bader, A. G. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.02.020 · Cited by 41

Design, synthesis, SAR discussion, in vitro and in vivo evaluation of novel selective EGFR modulator to inhibit L858R/T790M double mutants

Zhang, H., Wu, W., Feng, C., Liu, Z., Bai, E., Wang, X., Lei, M., Cheng, H., Feng, H., Shi, J., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.036 · Cited by 41

Glucose metabolism‐targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor‐induced drug‐tolerant persisters

Kunimasa, K., Nagano, T., Shimono, Y., Dokuni, R., Kiriu, T., Tokunaga, S., Tamura, D., Yamamoto, M., TACHIHARA, M. Y., Kobayashi, K., et al. (2017) · Cancer Science · doi:10.1111/cas.13266 · Cited by 42

Hyperoside exhibits anticancer activity in non‑small cell lung cancer cells with T790M mutations by upregulating FoxO1 via CCAT1

Hu, Z., Zhao, P., & Xu, H. (2019) · Oncology Reports · doi:10.3892/or.2019.7440 · Cited by 41

EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models

Venugopalan, A., Lee, M.-J., Niu, G., Medina-Echeverz, J., Tomita, Y., Lizak, M. J., Cultraro, C. M., Simpson, R. M., Chen, X., Trepel, J. B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11021 · Cited by 40

A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity

Ai, X., Sun, Y., Wang, H., & Lü, S. (2014) · Amino Acids · doi:10.1007/s00726-014-1716-0 · Cited by 40

Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value

Alegre, E., Fusco, J. P., Restituto, P., Salas‐Benito, D., Rodriguez-Ruiz, M. E., Andueza, M. P., Pajares, M. J., Patiño‐García, A., Pı́o, R., Lozano, M. D., et al. (2016) · Tumor Biology · doi:10.1007/s13277-016-5282-9 · Cited by 40

Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib

Mu, Y., Hao, X., Yang, K., Ma, D., Wang, S., Xu, Z., Li, J., & Xing, P. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00644-6 · Cited by 39

Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer

Cao, F., Gong, Y., Kang, X., Lu, Z., Wang, Y., Zhao, K., Miao, Z., Liao, M., & Xu, Z. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.114662 · Cited by 39

Celastrol acts synergistically with afatinib to suppress non‐small cell lung cancer cell proliferation by inducing paraptosis

Dai, C., Zhu, L., Wang, Y., Tang, X., Du, Y., Chen, Y. E., & Li, J. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30172 · Cited by 39

Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles

Juan, A., Noblejas‐López, M. D. M., Arenas-Moreira, M., Alonso‐Moreno, C., & Ocaña, A. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.805336 · Cited by 39

Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer

Zámečnı́kova, A. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.865012 · Cited by 40

Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer

Yap, T. A., Macklin-Doherty, A., & Popat, S. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.014 · Cited by 38

Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma

Liang, J., Bi, G., Sui, Q., Zhao, G., Zhang, H., Bian, Y., Chen, Z., Huang, Y., Xi, J., Shi, Y., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113771 · Cited by 38

Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer

Mancini, M., Gaborit, N., Lindzen, M., Salame, T. M., Dall’Ora, M., Sevilla-Sharon, M., Abdul‐Hai, A., Downward, J., & Yarden, Y. (2015) · Science Signaling · doi:10.1126/scisignal.aaa0725 · Cited by 38

Targeted therapies and immunotherapy in non-small-cell lung cancer

Cortinovis, D. L., Abbate, M. I., Bidoli, P., Capici, S., & Canova, S. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2016.648 · Cited by 37

AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells

Zhang, Z., Zhang, M., Liu, H., & Yin, W. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27434 · Cited by 38

Ultra-sensitive EGFR T790M Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring EGFR del19 Mutations and Treated with First-generation TKIs

Vendrell, J. A., Mazières, J., Senal, R., Rouquette, I., Quantin, X., Pujol, J.-L., Roch, B., Bouidioua, A., Godreuil, S., Coyaud, É., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2683 · Cited by 40

Potent and Selective Inhibitors of the Epidermal Growth Factor Receptor to Overcome C797S-Mediated Resistance

Finlay, M. R. V., Barton, P., Bickerton, S., Biśta, M., Colclough, N., Cross, D. A. E., Evans, L., Floc’h, N., Gregson, C. L., Guerot, C. M., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01055 · Cited by 39

Update on systemic therapy of advanced non-small-cell lung cancer

Čufer, T., & Knez, L. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.940327 · Cited by 37

Durable Response of Spinal Chordoma to Combined Inhibition of IGF-1R and EGFR

Aleksic, T., Browning, L., Woodward, M., Phillips, R. R., Page, S., Henderson, S. J., Athanasou, N. A., Ansorge, O., Whitwell, D., Pratap, S., et al. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00098 · Cited by 37

A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib

Lee, J. Y., Sun, J.-M., Lim, S. H., Kim, H. S., Yoo, K. H., Jung, K. S., Song, H.-N., Ku, B. M., Koh, J., Bae, Y.-H., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1653 · Cited by 36

Molecular genetic testing for lung adenocarcinomas: a practical approach to clinically relevant mutations and translocations

Đačić, S. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201336 · Cited by 36

Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice

Faehling, M., Schwenk, B., Kramberg, S., Eckert, R., Volckmar, A., Stenzinger, A., & Sträter, J. (2017) · Oncotarget · doi:10.18632/oncotarget.20857 · Cited by 35

Re-biopsy by endobronchial ultrasound procedures for mutation analysis of non-small cell lung cancer after EGFR tyrosine kinase inhibitor treatment

Izumo, T., Matsumoto, Y., Chavez, C., & Tsuchida, T. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0268-3 · Cited by 35

Histone code and long non-coding RNAs (lncRNAs) aberrations in lung cancer: implications in the therapy response

Herrera‐Solorio, A. M., Armas‐López, L., Arrieta, O. G., Zúñiga, J., Piña‐Sánchez, P., & Ávila‐Moreno, F. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0398-3 · Cited by 34

Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations

Masago, K., Fujita, S., Muraki, M., Hata, A., Okuda, C., Otsuka, K., Kaji, R., Takeshita, J., Kato, R., Katakami, N., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1925-2 · Cited by 33

In vivo efficacy studies of novel quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors, in lung cancer xenografts (NCI-H1975) mice models

Das, D., Xie, L., Wang, J., Shi, J., & Hong, J. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103790 · Cited by 33

Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation

Tian, T., Yu, M., Li, J., Jiang, M.-Q., Ma, D., Tang, S., Lin, Z., Chen, L., Gong, Y., Zhu, J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.739090 · Cited by 32

Optimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung Cancer

Meador, C. B., Jin, H., de Stanchina, E., Nebhan, C. A., Pirazzoli, V., Wang, L., Wang, L., Vuong, H., Hutchinson, K. E., Jia, P., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0723 · Cited by 31

Novel agents in development for advanced non-small cell lung cancer

Stinchcombe, T. E. (2014) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014532510 · Cited by 32

Non–Small-Cell Lung Cancer: Then and Now

Schiller, J. H., Gandara, D. R., Goss, G. D., & Vokes, E. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.5772 · Cited by 32

Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer

Jang, J.-Y., Kim, Y.-G., Nam, S. J., Keam, B., Kim, T. M., Jeon, Y. K., & Kim, C. W. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0089 · Cited by 31

Circulating DNA addresses cancer monitoring in non small cell lung cancer patients for detection and capturing the dynamic changes of the disease

Wei, Z., Shah, N., Deng, C., Xiao, X., Zhong, T., & Li, X. (2016) · SpringerPlus · doi:10.1186/s40064-016-2141-5 · Cited by 32

Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy

Concha-Benavente, F., & Ferris, R. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00332 · Cited by 28

A Small Molecule with Anticancer and Antimetastatic Activities Induces Rapid Mitochondrial-Associated Necrosis in Breast Cancer

Bastian, A., Thorpe, J. E., Disch, B. C., Bailey‐Downs, L. C., Gangjee, A., Devambatla, R. K. V., Henthorn, J., Humphries, K. M., Vadvalkar, S. S., & Ihnat, M. A. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.220335 · Cited by 31

MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor

Chen, Y., Li, R. Q., Pan, M., Shi, Z., Yan, W., Liu, N., You, Y., Zhang, J., & Wang, X. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2463-3 · Cited by 31

A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer

Kelly, R. J., Shepherd, F. A., Krivoshik, A., Jie, F., & Horn, L. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz128 · Cited by 31

A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs

Park, J. S., Hong, M. H., Chun, Y. J., Kim, H. R., & Cho, B. C. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.030 · Cited by 31

Mass Spectrometry as a Highly Sensitive Method for Specific Circulating Tumor DNA Analysis in NSCLC: A Comparison Study

Lamy, P., van der Leest, P., Lozano, N., Becht, C., Duboeuf, F., Groen, H. J. M., Hilgers, W., Pourel, N., Rifaela, N., Schuuring, E. M. D., et al. (2020) · Cancers · doi:10.3390/cancers12103002 · Cited by 31

Discordance of Mutation Statuses of Epidermal Growth Factor Receptor and K-ras between Primary Adenocarcinoma of Lung and Brain Metastasis

Rau, K., Chen, H.-K., Shiu, L., Chao, T.-L., Lo, Y.-P., Wang, C., Lin, M., & Huang, C. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040524 · Cited by 31

The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations

Liu, C., Wang, C., Li, S., Hsu, P., Chen, C., Lin, T., Kuo, C. S., Fang, Y., Ko, H., Yu, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18746 · Cited by 30

Design, Synthesis and Biological Evaluation of the Quinazoline Derivatives as L858R/T790M/C797S Triple Mutant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Zhang, M., Wang, Y., Wang, J., Liu, Z., Shi, J., Li, M., Zhu, Y., & Wang, S. (2020) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c20-00411 · Cited by 30

Rapamycin Prevents the Development and Progression of Mutant Epidermal Growth Factor Receptor Lung Tumors with the Acquired Resistance Mutation T790M

Kawabata, S., Mercado-Matos, J., Hollander, M. C., Donahue, D., Wilson, W., Regales, L., Butaney, M., Pao, W. J., Wong, K., Janne, P. A., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.05.039 · Cited by 30

BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations

Cardona, A. F., CLICaP, O. B. O. T., Rojas, L., Wills, B., Arrieta, O., Carranza, H., Vargas, C., Otero, J., Corrales-Rodriguez, L., Martín, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12112 · Cited by 29

Dynamic changes of acquired T790M mutation and small cell lung cancer transformation in a patient with EGFR-mutant adenocarcinoma after first- and third-generation EGFR-TKIs: a case report

Ma, S., He, Z., Fu, H., Wang, L., Wu, X., Zhang, Z., & Wang, Q. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.01.07 · Cited by 30

The Significance of MMP-1 in EGFR-TKI–Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting

Saito, R., Miki, Y., Ishida, N., Inoue, C., Kobayashi, M., Hata, S., Yamada‐Okabe, H., Okada, Y., & Sasano, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020609 · Cited by 27

MET receptor in oncology: From biomarker to therapeutic target

Malik, R., Mambetsariev, I., Fricke, J., Chawla, N. S., Nam, A., Pharaon, R. R., & Salgia, R. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.04.006 · Cited by 29

Drug Resistance Missense Mutations in Cancer Are Subject to Evolutionary Constraints

Friedman, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082059 · Cited by 29

Somatic DNA mutation analysis in targeted therapy of solid tumours.

Yu, B., O'Toole, S. A., & Trent, R. J. (2015) · PubMed Central · doi:10.3978/j.issn.2224-4336.2015.04.04 · Cited by 29

T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non–Small Cell Lung Cancer

Watanabe, S., Yoshida, T., Kawakami, H., Takegawa, N., Tanizaki, J., Hayashi, H., Takeda, M., Yonesaka, K., Tsurutani, J., & Nakagawa, K. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0351 · Cited by 30

Combined effect of cabozantinib and gefitinib in crizotinib‐resistant lung tumors harboring ROS 1 fusions

Kato, Y., Ninomiya, K., Ohashi, K., Tomida, S., Makimoto, G., Watanabe, H., Kudo, K., Matsumoto, S., Umemura, S., Goto, K., et al. (2018) · Cancer Science · doi:10.1111/cas.13752 · Cited by 28

Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma

Su, K., Tseng, J., Liao, K.-M., Yang, T., Chen, K., Hsu, K.-H., Yang, P., Yu, S., & Chang, G. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207001 · Cited by 29

Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects

Shi, C., Wang, Y., Xue, J., & Zhou, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940288 · Cited by 31

Systems biology approaches to develop innovative strategies for lung cancer therapy

Viktorsson, K., Lewensohn, R., & Zhivotovsky, B. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.28 · Cited by 27

Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs

Brueckl, W. M., Tufman, A., & Huber, R. M. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1266265 · Cited by 27

Antiproliferation effect of imatinib mesylate on MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines via PDGFR-β, PDGF-BB, c-Kit and SCF genes

Kadivar, A., Kamalıdehghan, B., Javar, H. A., Karimi, B., Sedghi, R., & Noordin, M. I. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s124102 · Cited by 27

A large-scale, multicentered trial evaluating the sensitivity and specificity of digital PCR versus ARMS-PCR for detecting ctDNA-based EGFR p.T790M in non-small-cell lung cancer patients

Xu, J., Wu, W., Wu, C., Mao, Y., Qi, X., Guo, L., Lu, R., Xie, S., Lou, J., Zhang, Y., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-564 · Cited by 26

Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies

Carrera, S., Buqué, A., Azkona, E., Aresti, U., Calvo, B., Sancho, A., Arruti, M., Nuño, M., Rubio, I., de Lobera, A. R., et al. (2013) · Clinical & Translational Oncology · doi:10.1007/s12094-013-1143-9 · Cited by 26

Combination of tissue and liquid biopsy molecular profiling to detect transformation to small cell lung carcinoma during osimertinib treatment

Vendrell, J. A., Quantin, X., Serre, I., & Solassol, J. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920974192 · Cited by 26

CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in Egfr -Mutant Lung Cancer

Nishii, K., Ohashi, K., Tomida, S., Nakasuka, T., Hirabae, A., Okawa, S., Nishimura, J., Higo, H., Watanabe, H., Kano, H., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0751 · Cited by 26

Monitoring Reversal of MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer Using 3′-Deoxy-3′-[18F]-Fluorothymidine Positron Emission Tomography

Iommelli, F., Rosa, V. D., Gargiulo, S., Panico, M., Monti, M., Greco, A., Gramanzini, M., Ortosecco, G., Fonti, R., Brunetti, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0264 · Cited by 26

Modification of cytokine-induced killer cells with chimeric antigen receptors (CARs) enhances antitumor immunity to epidermal growth factor receptor (EGFR)-positive malignancies

Ren, X., Ma, W., Lu, H., Yuan, L., An, L., Wang, X., Cheng, G., & Zuo, S. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1757-6 · Cited by 25

Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy

Kim, J., Vasu, V. T., Mishra, R., Singleton, K. R., Yoo, M., Leach, S. M., Farias‐Hesson, E., Mason, R. J., Kang, J., Ramamoorthy, P., et al. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu323 · Cited by 25

Impact of EGFR mutations on treatment of non-small cell lung cancer

Johnson, B. E., Jackman, D. M., & Janne, P. A. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0309-3 · Cited by 7

Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management

Noronha, V., Rajendra, A., Joshi, A., Patil, V., Menon, N. N., & Prabhash, K. (2019) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_51_19 · Cited by 64

New Treatment Strategy for Patients with EGFR -Mutant Lung Cancer

Ninomiya, T., Takigawa, N., Toyooka, S., Hotta, K., Tanimoto, M., & Kiura, K. (2013) · Lung Cancer Management · doi:10.2217/lmt.13.63

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer

Chang, S., Chang, C., & Shih, J. (2011) · Cancers · doi:10.3390/cancers3022667 · Cited by 6

Overcoming Resistance to EGF Receptor Tyrosine Kinase Inhibitors in EGFR -mutated NSCLC

Saad, S., Huang, K., & Halmos, B. (2014) · Lung Cancer Management · doi:10.2217/lmt.14.35 · Cited by 1